Wong Gary, He Shihua, Wei Haiyan, Kroeker Andrea, Audet Jonathan, Leung Anders, Cutts Todd, Graham Jill, Kobasa Darwyn, Embury-Hyatt Carissa, Kobinger Gary P, Qiu Xiangguo
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
J Virol. 2015 Oct 21;90(1):392-9. doi: 10.1128/JVI.02331-15. Print 2016 Jan 1.
Infections with Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases. The paucity of prophylactics and therapeutics against SUDV is attributed to the lack of a small-animal model to screen promising compounds. By repeatedly passaging SUDV within the livers and spleens of guinea pigs in vivo, a guinea pig-adapted SUDV variant (SUDV-GA) uniformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 × 10(-2) 50% tissue culture infective doses (TCID50), was developed. Animals infected with SUDV-GA developed high viremia and died between 9 and 14 days postinfection. Several hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and coagulation abnormalities, were observed. Virological analyses and gross pathology, histopathology, and immunohistochemistry findings indicate that SUDV-GA replicates in the livers and spleens of infected animals similarly to SUDV infections in nonhuman primates. These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV.
A disease outbreak due to Ebola virus (EBOV), suspected to have emerged during December 2013 in Guinea, with over 11,000 dead and 28,000 infected, is finally winding down. Experimental EBOV vaccines and treatments were administered to patients under compassionate circumstances with promising results, and availability of an approved countermeasure appears to be close. However, the same range of experimental candidates against a potential disease outbreak caused by other members of the genus Ebolavirus, such as Sudan virus (SUDV), is not readily available. One bottleneck contributing to this situation is the lack of a small-animal model to screen promising drugs in an efficient and economical manner. To address this, we have generated a SUDV variant (SUDV-GA) that is uniformly lethal to guinea pigs. Animals infected with SUDV-GA develop disease similar to that of SUDV-infected humans and monkeys. We believe that this model will significantly accelerate the development of life-saving measures against SUDV infections.
苏丹病毒(SUDV)是埃博拉病毒属的成员,其感染会导致严重出血热,在超过50%的人类病例中会导致致命后果。针对SUDV的预防和治疗药物匮乏,原因是缺乏用于筛选有前景化合物的小动物模型。通过在豚鼠的肝脏和脾脏内反复传代SUDV,开发出了一种适应豚鼠的SUDV变体(SUDV-GA),该变体对这些动物具有一致的致死性,半数致死剂量(LD50)为5.3×10⁻² 50%组织培养感染剂量(TCID50)。感染SUDV-GA的动物出现高病毒血症,并在感染后9至14天死亡。观察到了SUDV感染的几个特征,包括淋巴结病、肝酶活性增加和凝血异常。病毒学分析以及大体病理学、组织病理学和免疫组织化学结果表明,SUDV-GA在受感染动物的肝脏和脾脏中的复制情况与在非人类灵长类动物中的SUDV感染相似。这些进展将加速针对未来因SUDV引发疾病爆发的特定医学对策的开发。
2013年12月疑似在几内亚出现的埃博拉病毒(EBOV)疫情最终逐渐平息,此次疫情导致超过11000人死亡,28000人感染。在同情性情况下向患者施用了实验性EBOV疫苗和治疗方法,取得了有前景的结果,并且一种获批的对策似乎即将问世。然而,针对由埃博拉病毒属其他成员(如苏丹病毒(SUDV))引发的潜在疾病爆发的同类实验候选药物并不容易获得。造成这种情况的一个瓶颈是缺乏一种以高效且经济的方式筛选有前景药物的小动物模型。为解决这一问题,我们培育出了一种对豚鼠具有一致致死性的SUDV变体(SUDV-GA)。感染SUDV-GA的动物所患疾病与感染SUDV的人类和猴子相似。我们相信,这个模型将显著加速针对SUDV感染的救命措施的开发。